A new report from the WHO has highlighted the lack of innovative new antibiotic treatments currently in the clinical pipeline, and has emphasized this as a concern in the face of rising antimicrobial resistance.
An analysis of a large, nationwide health insurance database reveals a rapid increase in multiple recurring Clostridium difficile infections in the United States.
In research presented at ECCMID 2017, scientists have suggested foods should be investigated as potential source of C. difficile.
This study delves aims to evaluate the efficacy of durancin 61A as an inhibitor of resistant clinical pathogens and to shed light on its mode of action.
A study including over 10,000 patients has demonstrated a lower risk of all-cause 30-day mortality when Clostridium difficile infections are treated with vancomycin as opposed to metronidazole.
This perspective discusses the urgent need for novel and efficient antimicrobial strategies against C. difficile and the authors evaluate the application of the acyldepsipeptides family of antibiotics to treat C. difficile infections.
